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ABSTRACT
Graft-versus-tumor effect is well recognized in allogeneic transplantation, but it appears to be disease specific
and relapse remains a significant problem. Furthermore, immune reconstitution after hematopoietic cell
transplantation is often delayed and incomplete. It is becoming increasingly clear that the immune system is
complex and that cooperation between innate and adaptive immunity is required to induce a productive
immune response. Progress in clinically applicable cell separation techniques and knowledge of the signals
required for effective immune activation have made adoptive therapy with T cells and NK cells a viable
treatment option. However, clinical efficacy with either cell type depends on in vivo expansion of the infused
product, which is facilitated through mechanisms that are active after lymphodeletion. Although successes have
been seen with several approaches, further study of immune biology, lymphocyte cooperation and the role of
regulatory T cells will lead to better strategies to exploit adoptive transfer of lymphocytes for therapeutic
benefit.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Immunotherapeutic approaches, including adop-
ive cellular therapy and vaccines, are playing an in-
reasingly important role in the treatment of malig-
ancies. The principles of adoptive immunotherapy
stablished in animal models have formed the basis for
he testing of therapeutic strategies for human tumors.
ranslating these approaches to the clinic has been
ifﬁcult due to issues of patient heterogeneity, cost,
vailability of clinically approved reagents, and the
equirement for Good Manufacturing Practice (GMP)
acilities. The central premise supporting the use of
doptively transferred lymphocytes, including natural
iller (NK) cells and T cells, is that they can exhibit
ore antitumor activity compared with endogenous
ymphocytes. For NK cells, alloreactivity may be in-
reased by donor selection (eg, killer immunoglobu-
in-like receptor [KIR] ligand–mismatched NK cell
onors). For T cells, the ability to apply ex vivo stimuli
an expand speciﬁc antitumor cells and also may serve
o overcome the negative inﬂuence of tumors encoun- vered in vivo (eg, T cell anergy). Although it is not the
ocus of this manuscript, the role of regulatory T cells
hould be acknowledged, especially given the recent
ork showing that interleukin (IL)-2 administration
ay expand regulatory T cells in vivo, which can lead
o inhibition of NK cell and T cell function.
The ﬁrst part of this article, written by Drs.
ooley and Miller, describes the use of NK cell–based
mmunotherapy. NK cells do not require presensiti-
ation for antitumor activity, and allogeneic NK cells
o not induce graft-versus-host (GVH) responses, fea-
ures that make NK cell–based therapies attractive.
urrent strategies use in vivo expansion of alloge-
eic NK cells to treat both hematologic malignan-
ies and solid tumors and also to optimize hemato-
oietic cell transplantation (HCT) protocols by
ncorporating NK cells. The primary advantage of
sing adoptively transferred T cells is these cells’
bility to speciﬁcally target tumor cells that express
mall peptides even if the intact target protein itself
s not expressed on the cell surface. A second ad-
antage is their potentially long clonal lifespan. In
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S. Cooley et al.34he second part of this article, Dr. June explains the
rinciples of adoptive transfer of T cells and strat-
gies to combine vaccination with adoptive T cell
ransfer to improve tumor speciﬁcity and killing.
he success of immunotherapy depends on the gen-
ration of adequate numbers of activated effector
ells that persist in vivo long enough to exhibit a
easurable antitumor response. In the third part of
he article, Dr. Schoenberger discusses recent dis-
overies on the role of CD4 helper T cells in inﬂu-
ncing the development of functional CD8 cytotoxic T
ymphocytes (CTLs). It is becoming increasingly clear
hat methods of immune activation that orchestrate mul-
iple effectors to work in concert will produce the most
ffective antitumor treatments. Adoptive transfer of lym-
hocytes will likely play a signiﬁcant role in these emerg-
ng strategies.
DOPTIVE TRANSFER AND IN VIVO EXPANSION OF
UMAN ALLOGENEIC NK CELLS TO TREAT CANCER
S. COOLEY AND J. S. MILLER)
iology of NK Cells
NK cells are effectors of the innate immune sys-
em characterized by the expression of CD56 and
onexpression of CD3. They were initially recognized
or their ability to lyse virally infected cells and tumors
ithout requiring previous sensitization. They medi-
te immediate, nonspeciﬁc killing of targets in a major
istocompatibility complex (MHC)-independent fash-
on, a property that makes them an attractive cell
opulation to exploit for antitumor immunotherapy.
K cell cytotoxity is regulated by the net balance of
ctivating and inhibitory signals transferred through
everal classes of receptors, including KIRs [1]. Sev-
ral of the inhibitory KIRs recognize class I HLA
igands (C1, C2, and Bw4), which protect against NK
ell autoreactivity. The absence of class I HLA expres-
ion by a target leaves it unable to inhibit the corre-
ponding KIR, rendering it susceptible to lysis by that
K cell.
arly Autologous NK Cell Adoptive Transfer
During the 1980s, several clinical trials investi-
ated adoptive immunotherapy with lymphocytes to
reat various malignancies. These early trials were
eveloped to generate autologous lymphokine-acti-
ated killer (LAK) cells by ex vivo expansion of pe-
ipheral blood mononuclear cells (PBMCs) with IL-2
timulation for 5 days. Patients were given autologous
AK with high-dose IL-2, and modest success was
een in lymphoma, melanoma, and renal cell cancer,
here it was shown that the cytotoxic activity was
ediated mainly by NK cells [2]. To decrease com-
lications of vascular leak consistently seen with high-
ose IL-2 therapy, several centers tested outpatient cow-dose IL-2 administration ( ex vivo IL-2–acti-
ated cells) and found that it safely increased the
umber of activated NK cells circulating in vivo. This
pproach but did not result in clinical beneﬁt, how-
ver. For example, a phase II trial conducted at the
niversity of Minnesota found no efﬁcacy in patients
ith chronic myelogenous leukemia, lymphoma, or
reast cancer [3].
We now understand that the failure of autologous
AK and NK cell therapies likely has been due in part
o the down-regulation of NK cell killing by inhibi-
ory KIR recognition of “self” class I MHC on tumor
ells. In addition, successful expansion of adoptively
ransferred lymphocytes depends on adequate lym-
hodepletion to “clear space” for the infused lympho-
ytes to compete for growth factors and cytokines.
urine studies have demonstrated effective antitumor
mmunity after preparative regimens that induced suf-
cient lymphopenia to allow homoeostatic T cell ex-
ansion in vivo [4]. This principle was ﬁrst conﬁrmed
n humans by Rosenberg’s group at the National In-
titutes of Health [5]. T cell lymphopenia was induced
y cyclophosphamide (60 mg/kg/day  2 days) fol-
owed by ﬂudarabine (25 mg/m2/day  5 days). This
i-Cy/Flu therapy allowed in vivo expansion of adop-
ively transferred cytotoxic T-lymphocytes with spec-
ﬁcity for melanoma cells, resulting in subsequent
linical efﬁcacy.
doptive Transfer and In Vivo Expansion of
llogeneic NK Cells
In attempts to bypass the limitations of autologous
K therapies, we and others have turned to adoptive
ransfer of allogeneic cells. Alloreactivity may be fur-
her increased by selecting donors based on KIR li-
and mismatch status with the patient. This strategy
redicts that the selection of a donor having a KIR
igand lacking in the patient will correspond to a
igher frequency of donor antihost reactive cells. This
pproach is supported by the work of Ruggeri et al.
6], who showed that in the setting of haploidentical
CT, stratifying patients by their KIR ligand match
r mismatch status selected for patients who engrafted
ith alloreactive NK cells and resulted in improved
utcomes for patients with myeloid leukemia. To de-
ermine the safety and in vivo expansion of haploiden-
ical related-donor NK cell infusions, we ﬁrst tested
hem in a nontransplantation setting, which is safer
ecause permanent engraftment is not expected.
urthermore, because there is less concern for
raft-versus-host disease (GVHD), this setting is
ore amenable to combination therapy with IL-2,
hich is important for inducing NK cell activation
nd expansion. We treated 43 patients with either
etastatic melanoma (n  10), metastatic renal cell
arcinoma (n  13), refractory Hodgkin’s disease
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Adoptive Therapy with T Cells/NK Cells 35n  1), or refractory acute myelogenous leukemia
AML) (n  19) [7]. The ﬁrst 17 patients were
reated with a low-intensity outpatient chemother-
py regimen consisting of intravenous cyclophosph-
mide (750 mg/m2) and methylprednisolone (1000
g/m2) on day 2, followed by NK cell infusions
in escalating doses) on day 0 and IL-2 (1.75  106
U/m2) daily for 14 days. NK cell expansion was
etermined using a polymerase chain reaction–
ased chimerism assay and was considered success-
ul if donor NK cells were measurable by the end of
L-2 therapy. This preparative chemotherapy regi-
en did not induce lymphopenia on the day of
nfusion, and, not surprisingly, none of these pa-
ients achieved in vivo donor NK cell expansion.
Two other preparative regimens aimed at avoiding
K cell rejection were tested. Seven non-AML pa-
ients received intravenous ﬂudarabine (25 mg/m2)
aily for 5 days (days6 to2), and 19 AML patients
eceived 1 or 2 doses of intravenous cyclophospha-
ide (60 mg/kg) and intravenous ﬂudarabine (25 mg/
2) (Hi-Cy/Flu) daily for 5 days. Although both reg-
mens induced absolute lymphopenia at day 0, the
on-AML patients were not neutropenic, and no in
ivo NK cell expansion was seen with the low-inten-
ity ﬂudarabine regimen. In contrast, the more intense
i-Cy/Flu regimen induced pancytopenia, and in vivo
xpansion of NK cells was seen in 8 of the 15 evaluable
atients. A representative donor–recipient pair is
hown in Figure 1A, which shows in vivo expansion by
he increased band density beyond day 2. The donor
K cells are easily identiﬁed as CD56/CD3 NK
ells in blood (Figure 1B) and are functional in cyto-
oxicity assays.
In contrast to ﬂudarabine alone, the Hi-Cy/Flu
reparative regimen induced a surge of endogenous
L-15 (Figure 1C). An inverse correlation between the
bsolute lymphocyte count and the IL-15 concentra-
ion (r  .62; P  .0001) was seen postchemo-
herapy. The increased IL-15 level after Hi-Cy/Flu
herapy may result from gut release due to toxicity
nduced by cyclophosphamide. Alternatively, the de-
reasing numbers of mature lymphocytes may lead to
ecreased utilization of IL-15 and a corresponding
ncrease in plasma IL-15 concentrations. The impor-
ance of IL-15 in NK cell homeostasis [8,9] is sup-
orted by the correlation between high levels and
uccessful NK expansion.
linical Efficacy Correlates with In Vivo NK
xpansion and KIR Ligand Mismatch
Five of 19 patients with poor-prognosis AML
chieved complete remissions after the Hi-Cy/Flu
egimen and NK cell infusion. Compared with pa-
ients who failed to clear leukemia, the patients in
emission had signiﬁcantly higher proportions of cir- lulating NK cells (35%  8% vs 1.5%  0.4%; P 
001) and cytotoxicity against K562 targets (50% 
0% vs 10%  5% at E:T 20:1; P  .01). These
ndings support the conclusion that allogeneic donor
K cells expand in vivo and contribute to efﬁcacy.
lthough it was not a donor selection criterion, we
valuated the KIR mismatch status in the AML co-
ort. Four of 19 patients exhibited alloreactivity based
n KIR ligand mismatch in the GVH direction. In-
erestingly, 3 of 4 (75%) patients with KIR ligand
ismatch, but only 2 of 15 (13%) patients with KIR
igand match, achieved complete remission. Although
ur study sample is small, these data support a role for
IR ligand mismatching or other strategies in pro-
oting alloreactivity to treat AML.
The NK products in this initial trial were prepared
rom single lymphapheresis collections using a GMP
mmunomagnetic CD3 depletion. The ﬁnal products,
fter overnight activation in IL-2, contained a median
K cell dose of 9.4  106 cells/kg (range, 4-13  106
ells/kg) (n  36). We thought that contaminating
cells might compete for NK cell expansion, and that
cells might lead to Epstein-Barr virus (EBV)-driven
ymphoproliferation; therefore, we modiﬁed the pro-
ess to include a CD56 selection step, resulting in
ncreased NK cell purity (90%  7% CD56/CD3
K cells compared with 38%  13% with CD3
epletion alone), and minimal contamination with
D19 B cells or CD14 monocytes. However, no
K expansion was seen in the ﬁrst 10 patients treated
ith the puriﬁed NK cell products. This failure to
xpand may be due to NK cell loss with more exten-
ive processing, where approximately 1/3 the NK cell
ecovery was seen compared with CD3 depletion, re-
ulting in an NK cell dose of 3.4 106 cells/kg (range,
.15-6.6  106 cells/kg). Alternatively, the contami-
ating B cells and monocytes removed in the 2-step
epletion strategy may serve critical roles in NK cell
ctivation or expansion. For example, we have shown
hat contact with autologous monocytes is important
or in vitro NK cell expansion [10]. We have returned
o CD3 depletion alone for the NK products in the
ngoing trial in AML.
We are currently studying adoptively transferred
llogeneic NK cells in several other settings. We are
sing the Hi-Cy/Flu preparative chemotherapy to in-
estigate NK cell expansion and antitumor activity in
atients with metastatic breast cancer, a disease known
o be responsive to NK cell killing in vitro. In addi-
ion, we are testing 2 strategies for incorporating al-
ogeneic NK cell therapy with HCT. The presence of
lloreactive NK cells during the early recovery phase
f a traditional transplantation protocol may contrib-
te to more potent antileukemic therapy, may increase
he tolerability of the preparative regimen by inducing
ore rapid neutrophil recovery, and may provide pro-onged immune therapy. Besides decreasing relapse
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S. Cooley et al.36ates by mediating direct antileukemia killing, NK
ells can improve outcomes after HCT by decreasing
he incidence of GVHD and increasing engraftment
6]. We are testing these hypotheses in patients with
igure 1. In vivo expansion of haploidentical NK cells correlates w
urve was established between donor and recipient cells by polym
percentage of donor cells shown above). Postinfusion recipient sam
xample, donor NK cells were detectable at day 2 and had expanded
emonstrates equal sample loading. (B) PBMCs were collected from
ubsets were measured by ﬂow cytometry. For the patient shown he
aryotype in this male patient. (C) Plasma was collected from patien
as collected before the NK cell infusion. The plotted lines represe
ohort. IL-15 concentrations, measured by enzyme-linked immuno
ompared with those who received Flu alone.oor-prognosis AML by infusing allogeneic NK cell troducts derived from haploidentical related donors
r from umbilical cord blood (UCB) before standard
aploidentical or UCB HCT after nonmyeloablative
ersus fully ablative preparative regimens, respec-
h endogenous IL-15 levels induced by Hi-Cy/Flu. (A) A standard
hain reaction ampliﬁcation of an HLA allele unique to the donor
ere tested for the presence of the unique donor HLA allele. In this
7, as evidenced by the increased band density. The -actin control
ts at day 14 after haploidentical NK cell infusion and lymphocyte
of all circulating cells were CD56/CD3 NK cells with a female
re and after the indicated preparative regimens. The day 0 sample
mean ( the standard error under the mean) of samples from each
t assay, were markedly higher in patients who received Hi-Cy/Fluith hig
erase c
ples w
by day
patien
re, 92%
ts befo
nt the
sorbenively.
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Adoptive Therapy with T Cells/NK Cells 37herapeutic Limitations of NK Cells
The therapeutic potential for adoptive transfer of
llogeneic NK cells has several limitations. Lympha-
heresis collections can produce only limited numbers
f NK cells. Although we have shown that in vivo NK
ell expansion is possible, its success remains unpre-
ictable, and the durability of the expanded cell pop-
lation is limited. In vivo expanded NK cell popula-
ions are heterogeneous, expressing variable KIR
epertoires that produce variable alloreactivity. Along
ith KIR ligand mismatch status, the antitumor efﬁ-
acy of NK cell therapy depends on the expression of
he appropriate activating ligands on the tumor cells.
or example, the lack of efﬁcacy of KIR-mismatched
ransplants in lymphoid leukemias may be due to their
ow expression of LFA-1 or NKG2D ligands. Future
trategies to enhance activating ligand expression on
eukemia cells is needed to make them more suscep-
ible to NK cell–mediated lysis.
uture Directions
Numerous strategies to address these limitations
re under active investigation. Irradiated cell lines
uch as NK92 and KHYG-1 may provide an inex-
austible supply of highly cytotoxic NK cells, but they
re IL-2–dependent and have very short in vivo sur-
ival. Techniques for ex vivo expansion of adult NK
ells are currently being reﬁned by several groups.
lternatively, large numbers of NK cells may be de-
ived from UCB sources [11]. UCB-derived NK cells
lso may exhibit superior in vivo expansion. Ex vivo
xpanded cells from any source can be genetically
odiﬁed to express tumor-speciﬁc receptors. For ex-
mple, the NK92 cell line has been transfected with a
himeric antigen receptor for HER2/neu, which con-
erred superior cytotoxicity against HER2/neu-posi-
ive targets [12]. Reﬁnements in the administration of
ymphodepleting chemotherapy may optimize the cy-
okine milieu for NK cell expansion. Furthermore,
elective depletion of regulatory T cells, which can
uppress NK cell proliferation and killing, also may
mprove the immune effector functions of the expand-
ng NK cells [13]. NK cells may be made more allo-
eactive by using antibodies to block inhibitory KIR
14] or more tumor reactive by targeting NK cell
ntibody-dependent cell-mediated cytotoxicity with
umor-speciﬁc monoclonal antibodies, such as ritux-
mab or trastuzumab. Many investigators have dem-
nstrated the role of allogeneic NK cells in the treat-
ent of various malignancies, either through adoptive
ransfer or as part of HCT. Ultimately, improvements
n techniques to generate adequate numbers of allo-
eactive NK cells and to make tumor cells more sus-
eptible to their effects will increase the clinical efﬁ-
acy of NK cell–based immunotherapy. eOMBINING VACCINES WITH ADOPTIVE
MMUNOTHERAPY AND PERIPHERAL BLOOD STEM
ELLS (C. H. JUNE)
rinciples of T Cell Adoptive Transfer
Studies conducted over the past several decades
ave uncovered a number of principles of adoptive
mmunotherapy using T cells, including to (1) avoid
he induction of immunogenicity of the infused cells,
2) prevent or delay cellular immunosenescence, (3)
aximize CD4 T cell help, and (4) induce host
ymphopenia with conditioning chemotherapy. Re-
ent studies show that the in vivo persistence and
ngraftment of tumor-inﬁltrating lymphocytes corre-
ates with telomere length and tumor regression in
atients with melanoma [15]. Many studies show that
he generation and/or maintenance of CD8 memory
equires CD4 cell help, [16] and clinical adoptive
ransfer studies have shown that the persistence of
ytotoxic CD8 effector T cells (CTLs) is enhanced
ith the concomitant administration of IL-2 or CD4
ells. Finally, host lymphodepletion may enhance the
ffectiveness of adoptively transferred T cells [4].
ymphodepletion eliminates regulatory T cells and
ther competing elements of the immune system that
ct as “cytokine sinks,” enhancing the availability of
ytokines such as IL-7 and IL-15 [17]. This hypoth-
sis has been tested clinically in patients with meta-
tatic melanoma and myeloma, where initial results
uggest that the efﬁcacy of adoptive transfer is im-
roved in patients rendered immunodeﬁcient by cy-
otoxic chemotherapy [5,18].
pproaches for Adoptive T Cell Therapy
Two basic approaches to T cell adoptive immuno-
herapy are currently being tested. The ﬁrst approach
nvolves isolating and activating antigen-speciﬁc T cells
rom peripheral blood or tumor specimens and then
lonally expand those antigen-speciﬁc cells in vitro by
arious approaches [19]. In the second approach, the
atient is primed with a vaccine before lymphocyte
arvest, followed by polyclonal ex vivo activation of
he input T cells, based on the assumptions that anti-
en-speciﬁc T cells are present and that they have
een primed in vivo (Figure 2). The ﬁrst approach will
uarantee antigen speciﬁcity but is costly and labor-
ntensive. The second approach is technically more
acile. Both approaches have been promoted by the
ealization that homeostatic expansion of transferred
ymphocytes can improve engraftment and effector
unctions in vivo [4].
trategies to Combine Therapeutic Vaccination
nd Adoptive T Cell Therapy
Therapeutic vaccination of patients is likely to
ucceed mainly in the setting of minimal residual dis-
ase and probably will require priming and booster
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S. Cooley et al.38accinations to improve or maintain immunity. A cor-
llary to this assumption is that therapies combining
accination with other biologic agents with distinct
ut complementary mechanisms of action are required
o achieve maximum beneﬁt. In mice, vaccines and
doptive transfer of cells in the setting of lymphopenia
esults in enhanced tumor immunity [4,20,21]. In hu-
ans with myeloma, idiotype vaccination of sibling
onors followed by adoptive transfer in the form of
llogeneic stem cell transplantation can result in the
nduction of potent tumor immunity [22]. Although
his approach is theoretically attractive, at present there
re only limited data in humans demonstrating the efﬁ-
acy of a combined vaccine and adoptive T cell transfer
pproach in the autologous setting.
Two phase I trials using autologous activated or
costimulated” T cells in patients undergoing trans-
lantation for hematologic malignancies have been
eported. In the ﬁrst trial, patients with relapsed or
hemotherapy refractory non-Hodgkin’s lymphoma
ere treated with CD34-selected HCT followed by
nfusion of autologous T cells stimulated with anti-
D3 and anti-CD28 [23]. Infusion of autologous co-
timulated T cells resulted in a rapid reconstitution of
ymphocyte counts. Importantly, the expanded cells
ere functionally superior to those obtained directly
rom the patients, as determined by interferon-gamma
nduction. Complete or partial responses were ob-
erved in 8 of the 17 patients receiving infusion. Build-
ng on the previous trial, the authors next examined
he role of pretransplantation immunization and T
ell add-back in autologous transplantation for multi-
le myeloma [18]. All patients received 2 doses of
revnar, the 7-valent pneumococcal conjugate vaccine
PCV), beginning 1 month after transplantation. Half
igure 2. Schema for adoptive transfer of autologous, vaccine-prim
ith vaccine on day 28, followed by lymphocyte harvest on day
xpansion and are reinfused on day 2 after lymphodepleting ch
dministration of booster vaccines.f the patients received an additional dose of Prevnar tweeks before cells were harvested for the transplant.
he harvested T cells were expanded in vitro. Patients
eceived a standard, non–lymphocyte-depleted, autol-
gous transplant after melphalan conditioning and
hen received costimulated expanded autologous T
ells either 14 days or 100 days posttransplantation.
rompt T cell recovery was observed in both patient
roups that received T cell add-back on day 14,
hereas the day-100 add-back groups remained sig-
iﬁcantly lymphopenic. Only those individuals who
eceived PCV-primed T cells early after transplanta-
ion developed and maintained protective levels of
ntipneumococcal antibodies, as well as PCV-speciﬁc
D4 responses. These data demonstrate that combi-
ation vaccine and adoptive immunotherapy compris-
ng a single pretransplantation vaccine and an early
osttransplantation infusion of antigen-primed, ex
ivo costimulated autologous T cells followed by post-
ransplantation booster immunizations decreased the
evere immunodeﬁciency associated with high-dose
hemotherapy and led to clinically relevant immunity
n adults within a month after transplantation. Al-
hough larger trials are needed, this pilot study pro-
ides a useful foundation for future strategies using
ombinations of tumor vaccines and costimulated T
ells in lymphodepleted patients with lymphoma or
ther hematologic malignancies.
Shu and Chang have developed an alternative ap-
roach using tumor-inﬁltrating lymphocytes that
hould circumvent many of the limitations posed by
doptive transfer. They and others have shown in
ice that tumor–draining lymph nodes harbor T cells
hat are not capable of mediating tumor rejection in
doptive transfer experiments. In contrast, if the
raining lymph node cells are activated in vitro, then
itro–expanded T cells. As shown here, eligible patients are primed
he autologous T cells undergo polyclonal in vitro activation and
erapy. Antigen-speciﬁc immune function is measured after theed, in v
14. T
emothhe cells gain the capacity to mediate tumor rejection
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Adoptive Therapy with T Cells/NK Cells 39fter adoptive transfer. In further studies, T cells were
solated from vaccine-primed lymph nodes obtained
rom patients with melanoma, renal cell carcinoma,
nd head and neck cancer. In the absence of antigen-
resenting cells, activation with anti-CD3 and anti-
D28 greatly enhanced subsequent T cell expansion
n IL-2 ( 100-fold) compared with anti-CD3 alone
24]. Based on these and other preclinical studies, Chang
nd coworkers carried out a phase I trial in patients with
ate-stage melanoma and renal cell carcinoma [25]. Pa-
ients were given intradermal vaccination with irradi-
ted autologous tumor cells. The draining lymph
odes were harvested 7-10 days later, at which point
he vaccine-primed T cells were cultured and infused.
mong the 11 patients with melanoma, 1 had a partial
umor response; the 12 patients with renal cell carci-
oma included 2 complete and 2 partial responses.
hus there may be some clinical activity with this
pproach, and it could be adapted for hematologic
alignancies, particularly for lymphoma therapy.
With the exception of idiotype and EBV-induced
ymphoproliferative disease, an obstacle to combined
accine and adoptive T cell therapy of hematologic
alignancies is that the optimal tumor antigens re-
ain undeﬁned. A unique and truly antigen-speciﬁc
arget is the idiotype antigen receptor present on
any lymphomas and myelomas. Idiotype has proven
o be a robust target for vaccine strategies for patients
ith follicular lymphomas [26], and in preclinical
odels, T cells have been shown to target idiotype
27]. However, clinical attempts to target the idiotype
ith adoptively transferred T cells have not yet been
uccessful. A more widely applicable form of cellular
herapy could be developed with the identiﬁcation of
niversal tumor antigens that are (1) presented by
ost MHC types, (2) expressed and presented in most
umors, (3) expressed in limited amounts in normal
issues, and (4) directly involved in the malignant
henotype of the tumor. Recent studies have identi-
ed several candidates for universal tumor antigens,
ncluding the catalytic subunit of telomerase (hTERT),
ytochrome P450 isoform 1B1, survivin, proteinase 3,
T-1, and MDM2.
doptive T Cell Therapy: Dose and Scheduling
ssues
Information on the dose and schedule dependence
f adoptively transferred T cells is widely scattered in
he literature, and no standardized dose system has
een described. Schedule-dependent efﬁcacy and ad-
erse effects from adoptively transferred cells have
een reported. There is evidence in nonlymphopenic
osts suggesting that fractionated doses of adoptively
ransferred T cells are superior to a single infusion of
cells [28]. The ideal dose of transferred cells is
elated to the tumor burden and to the homing and
ersistence (memory) characteristics of the infused yells. Doses of adoptively transferred cells are usually
eported as the total number of viable cells adminis-
ered or as the total number of viable cells per kg body
eight or per square meter body surface area. How-
ver, total lymphocyte numbers do not correlate well
ith body surface area and in fact display a stronger
nverse correlation with age. Other variables add to
he complexity, particularly when using T cells or
ther adoptively transferred cells with high replicative
otential. The infused dose may not relate well to the
teady-state number of cells. Therefore, dosage con-
iderations are more complex than in other areas of
ransfusion medicine where, for example, the maximal
evel of transfused red cells or platelets occurs imme-
iately after infusion. Recent studies of adoptively
ransferred autologous CD4 T cells found that the
ighest number of cells in the host peaked 2 weeks
fter cell infusion [29]. This is because the engraft-
ent potential and the replicative potential of the
nfused cells depends on complex host variables, such
s the number of niches available in the host for
ngraftment and the antigenic stimulus for clonal ex-
ansion or deletion [17]. In most rodent tumor mod-
ls, T cell proliferation in the host after transfer is
bligatory for therapeutic efﬁcacy [30].
Many studies in rodent tumor models have shown
hat the coadministration of cytotoxic therapy can
nhance the effects of adoptively transferred cells.
urrently, cyclophosphamide and ﬂudarabine are the
referred agents. The mechanism is likely due not to
ytoreduction, but rather to multiple other effects,
ncluding (1) the killing of host regulatory lympho-
ytes that suppress antitumor immune responses, (2)
he creation of “space” in the host so that the adop-
ively transferred cells can engraft, and perhaps (3)
nhanced cross-priming of tumor antigens. Curti et al.
31] examined a related issue concerning the optimal
ime for harvesting autologous T cells in relation to
he timing of cyclophosphamide administration in pa-
ients with lymphoma and other advanced cancers. T
ells were harvested at steady state, when declining, or
hen recovering after cyclophosphamide-induced
eukopenia. These authors concluded that the best
ime to harvest autologous T cells was not at steady
tate, but rather just before the leukopenic nadir after
yclophosphamide administration. The optimum in
ivo expansion of the infused CD4 T cells occurred
hen the cells had been harvested as patients entered
he cyclophosphamide-induced nadir. Most of the
linical antitumor responses also occurred in patients
reated on this schedule. These results are generally
onsistent with animal models that predicted a need to
blate immunosuppressive lymphocytes for efﬁcient
ngraftment and subsequent in vivo expansion of
doptively transferred CD4 T cells.
In patients with early-stage cancers who have not
et received cytotoxic chemotherapy, it is probably
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S. Cooley et al.40est to harvest autologous T cells before initiation of
hemotherapy. This recommendation is based on the
imited regeneratative capacity of T cells from the
dult thymus. After chemotherapy, the repertoire re-
ains contracted for long periods, and in many cases
t never recovers. Naive T cells are most sensitive to
he effects of cytotoxic chemotherapy, and their num-
ers are severely depleted in heavily pretreated pa-
ients. It is not yet known whether the antitumor
peciﬁc T cells are derived from primed or naive T
ells in the host; this likely varies depending on the
ntrinsic immunogenicity of the tumor.
ummary
It is likely that adoptive immunotherapy will not
e used alone, but rather will be combined with vac-
ines, chemotherapy, and other forms of immunother-
py. Based on the pioneering work of Kwak and
evy [32], idiotype-speciﬁc vaccines for patients
ith follicular lymphoma are likely to be approved
oon, providing an important opportunity to com-
ine therapeutic vaccines with adoptive T cell transfer
herapy.
HE TRAIL FROM T HELPER TO CD8 T CELL
EMORY (S. SCHOENBERGER)
The successful clinical application of adoptive im-
unotherapy will require a clearer understanding of
he cellular and molecular pathways governing the
esponse of key effector populations. Recent studies
ave provided new insight into the role of CD4
elper T cells in inﬂuencing the signals that control
he functional development and survival of MHC class
–restricted CD8 CTLs [16]. The focus of much of
his work has been on determining how the signals
ransmitted antigen-presenting cells after activation
y CD4 helper T cells are integrated into the CTL
esponse. These signals induce CTLs to (1) undergo
rimary expansion, (2) acquire effector function, and
3) give rise to a subset that become bona ﬁde memory
ells that are endowed with 2 additional functional
apacities: enhanced survival and secondary expansion
n reencounter with antigen. Several lines of evidence
ndicate that each of these fates is directed largely by
n instructional “program” that is set into motion by
nductive signals received during priming of clonal
recursors, and is then carried out by their postexpan-
ion progeny [33]. Identifying the essential elements
f this program, along with the signals and molecular
athways through which it is encoded and executed,
ill provide the information needed to generate and
aintain clinically beneﬁcial CTL responses in adop-
ive therapy. A necessary ﬁrst step is to deﬁne the
arameters of CTL function inﬂuenced by the pres-
nce or absence of CD4 T cell help. selp for Secondary Expansion
The effectiveness of a given population of antigen-
peciﬁc CTLs depends on the capacity of selected
lones to expand their numbers through division. Al-
hough the primary burst may increase the initial
requency of a given clone by 100- to 1000-fold or
ore, these cells will undergo a contraction phase
uring which 90%–95% of their numbers are lost
34]. The capacity of these primary CTLs to undergo
second round of division should be considered a
rucial aspect of functional immune memory, because
t allows the primary clonal progeny to reach the
igher frequencies needed to deal with a substantial
arget cell population, such as might exist within a
umor or virally infected organ. It was noted by 4
roups, all working with distinct antigenic systems,
hat a central function of CD4 T cell help is to
ndow CTLs with the capacity for secondary expan-
ion after restimulation in vitro and in vivo [16]. Stud-
es using physiological numbers of precursors have
emonstrated that the help appears to confer the
unctional capacity for secondary expansion during
he ﬁrst 1-2 days of priming. This ﬁnding is con-
istent with a role for CD4 T cells in modifying
he instructional program of CTL development to
nclude secondary expansion [35]. In contrast, adop-
ive-transfer models studying high numbers of
ntigen-speciﬁc transgenic CTLs after an acute in-
ection have shown that CD4 T cells appear to
xert their inﬂuence over a longer period. Curi-
usly, this “maintenance” capacity does not appear
o require antigen speciﬁcity [36].
elp for Survival?
The observation that CTLs acquire the capacity
or secondary expansion through an early modiﬁcation
f their developmental program that occurs during
riming in the presence of help was the basis for the
ypothesis that the “helped” cells would follow a spe-
iﬁc pattern of gene expression distinct from their
helpless” counterparts. To document this, we fol-
owed the fate of helpless CTLs after restimulation. In
ontrast to the helped cells that undergo secondary
xpansion, we found that the helpless CTLs undergo
ctivation-induced cell death (AICD). The apopto-
is is mediated by the expression of TNF-related
poptosis inducing ligand (TRAIL)/apo2L, a mem-
er of the TNF superfamily of death receptor/
igand pairs [37-39]. TRAIL expression was found
o be regulated by selective transcription in the
elpless cells, although antigenic stimulation in-
uced expression of the TRAIL receptor (TRAIL-
2/DR5) in both helped and helpless CTLs. This
aises the possibility that memory CTLs can be
ade to undergo TRAIL-R-mediated AICD on re-
timulation [37]. Notably, the TRAIL produced by
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Adoptive Therapy with T Cells/NK Cells 41he restimulated helpless cells is in a soluble form,
uggesting that it may be able to exert an immuno-
egulatory effect on neighboring T cells or even on
ntigen-presenting cells [40].
uture Perspectives
This information regarding CD4 T cell help and
he role of TRAIL in the regulation of CTL responses
heds new light on questions critical to the ﬁeld of
doptive immunotherapy and suggests future avenues
f investigation. The identiﬁcation of the signals that
irect the differentiation of CTLs toward the helped
athway during primary activation remains an impor-
ant problem. Understanding the mechanism through
hich these inductive stimuli are “hard-wired” into
TLs, preserved throughout clonal expansion, and
ntegrated into the response of the CTL progeny will
ffer a novel perspective on the molecular regulation
f differentiation. Finally, the idea that helpless CTLs
roduce a soluble form of TRAIL on antigenic stim-
lation raises the possibility that such cells can be
numerated through an enzyme-linked immunospot
ssay, which would provide a direct, useful phenotypic
easurement of T cells in identifying populations for
se in adoptive immunotherapy.
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